13 Days
Source:
The Boston Globe
_1777370220974_847775619.png&w=48&q=75){kind=small}
FDA reviews updated mRNA flu shot
U.S. health advisers are reviewing Moderna's mRNA flu vaccine, mFlusiva, seeking FDA approval for use in adults aged 50 and older. The vaccine aims to offer faster manufacturing and better protection by matching circulating flu strains more closely. A study showed it reduced flu cases by about 27%, and the FDA has reported no safety concerns, with a final decision upcoming before the winter flu season.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)